Immunohistochemistry Combined with NGS to Assist the Differential Diagnosis of Multiple Primary Lung Cancer with Lymph Node Metastasis: a Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Nov 3

PMID 37920154

Authors

Chang Liu

Shuai Zhang

Hong Yang

Yu Bai

Yanru Shen

Yi Ren

Affiliations

Soon will be listed here.

Abstract

In recent years, the incidence of synchronous multiple primary lung cancers (MPLCs) has gradually increased. Surgery is the preferred treatment for these patients. There are great differences in the driving genes between individual tumors in patients with MPLC, and tumors with targeted mutations do not represent other tumors, which challenges the selection of targeted therapies for patients with MPLC. Driving mutations in each lesion after surgery are crucial for establishing accurate pathological staging and subsequent treatment strategies. There are some mutated genes in the lymph nodes of postoperative metastatic MPLCs, and the tumor cell count/DNA concentration is low, which limits the next-generation sequencing (NGS) detection effect. A combination with immunohistochemistry to determine the source of metastasis may be a better choice. This study reports a rare case of lung cancer with double primary adenocarcinomas of the lung combined with 10 groups of lymph node metastases. The source of metastasis was identified using immunohistochemistry combined with NGS to guide postoperative adjuvant treatment. We hope that this case report can provide new ideas for the identification of MPLCs and assist in their diagnosis and individualized treatment. In addition, the combination specific immunohistochemistry and NGS seems to be an effective identification method. This approach can provide clinical benefits; however, this still requires further exploration through studies with large sample sizes.

References

Zhao L, Liu C, Xie G, Wu F, Hu C . Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine. Cancer Manag Res. 2020; 12:10361-10374. PMC: 7585808. DOI: 10.2147/CMAR.S268081. View

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

Li J, Yang X, Xia T, Guan Y, Zhong N . Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis. J Thorac Dis. 2018; 9(12):5335-5344. PMC: 5757034. DOI: 10.21037/jtd.2017.12.101. View

Kozower B, Larner J, Detterbeck F, Jones D . Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e369S-e399S. DOI: 10.1378/chest.12-2362. View

Romaszko A, Doboszynska A . Multiple primary lung cancer: A literature review. Adv Clin Exp Med. 2018; 27(5):725-730. DOI: 10.17219/acem/68631. View

Seo A, Park T, Jin Y, Sun P, Kim H, Chang H . Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer. 2014; 83(3):316-23. DOI: 10.1016/j.lungcan.2013.12.008. View

Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D . Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res. 2009; 15(16):5184-90. PMC: 2892178. DOI: 10.1158/1078-0432.CCR-09-0594. View

Detterbeck F, Jones D, Kernstine K, Naunheim K . Lung cancer. Special treatment issues. Chest. 2003; 123(1 Suppl):244S-258S. DOI: 10.1378/chest.123.1_suppl.244s. View

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J . Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. J Thorac Oncol. 2019; 14(5):844-856. DOI: 10.1016/j.jtho.2019.01.017. View

10.

Wu C, Zhao C, Yang Y, He Y, Hou L, Li X . High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol. 2015; 10(5):778-783. DOI: 10.1097/JTO.0000000000000487. View

11.

Liu M, He W, Song N, Yang Y, Zhang P, Jiang G . Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg. 2016; 50(5):909-913. DOI: 10.1093/ejcts/ezw113. View

12.

Chen B, Li R, Zhang J, Xu L, Jiang F . Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer. Pathol Oncol Res. 2022; 28:1610020. PMC: 9243222. DOI: 10.3389/pore.2022.1610020. View

13.

Gazdar A, Minna J . Multifocal lung cancers--clonality vs field cancerization and does it matter?. J Natl Cancer Inst. 2009; 101(8):541-3. PMC: 2669103. DOI: 10.1093/jnci/djp059. View

14.

Moskalev E, Stohr R, Rieker R, Hebele S, Fuchs F, Sirbu H . Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch. 2013; 462(4):409-19. PMC: 3624006. DOI: 10.1007/s00428-013-1376-6. View